Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Ottawa

$105,000.00

The development of effective TNBC treatment through the co-inhibition of SCD1 and NF-kB pathways

EF 2019-20

Résumé
Triple negative breast cancer (TNBC) is an aggressive form of breast cancer, accounting for the majority of breast cancer related deaths. Chemotherapy remains the primary treatment option for patients with TNBC but leads to the enrichment of a subpopulation of cells with tumor initiating capacities called cancer stem cells (CSCs). Breast CSCs are responsible for chemotherapy resistance, metastasis and recurrence. Previous research has shown that lipid metabolism, specifically the enzyme stearoyl-CoA-desaturase (SCD1) is involved in the maintenance of CSCs. However, the inhibition of SCD1 alone is not effective as it is controlled by another signalling pathway known as the NF-kB pathway, which is also crucial for CSC survival. In this proposed work, I will show the need to inhibit both signalling pathways, SCD1 and NF-kB, as they activate each other and contribute to CSC survival and enrichment. I will use a clinically translatable and accurate tumor model where tumors extracted from actual patients will be implanted in mice to test the treatment success. In this way, I will accurately investigate the effect of the CSC pathway inhibition on reversing chemotherapy resistance and increasing treatment efficiency in TNBC. Our research is geared towards improving population health as it aims to combat this aggressive form of breast cancer by developing a therapeutic strategy to be used in the clinic while improving our understanding of breast cancer resistance.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
417177
Name
El-Sahli Sara
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Doctoral Research Awards - A
Projecttitle
The development of effective TNBC treatment through the co-inhibition of SCD1 and NF-kB pathways
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Cancer Metabolism; Cancer Stem Cells; Cancer Therapy; Flow Cytometry; Gene Expression; Nf-Kb Signaling; Patient Derived Xenograft Model; Scd1 Signaling; Triple Negative Breast Cancer; Tumor Growth
Abstract
Triple negative breast cancer (TNBC) is an aggressive form of breast cancer, accounting for the majority of breast cancer related deaths. Chemotherapy remains the primary treatment option for patients with TNBC but leads to the enrichment of a subpopulation of cells with tumor initiating capacities called cancer stem cells (CSCs). Breast CSCs are responsible for chemotherapy resistance, metastasis and recurrence. Previous research has shown that lipid metabolism, specifically the enzyme stearoyl-CoA-desaturase (SCD1) is involved in the maintenance of CSCs. However, the inhibition of SCD1 alone is not effective as it is controlled by another signalling pathway known as the NF-kB pathway, which is also crucial for CSC survival. In this proposed work, I will show the need to inhibit both signalling pathways, SCD1 and NF-kB, as they activate each other and contribute to CSC survival and enrichment. I will use a clinically translatable and accurate tumor model where tumors extracted from actual patients will be implanted in mice to test the treatment success. In this way, I will accurately investigate the effect of the CSC pathway inhibition on reversing chemotherapy resistance and increasing treatment efficiency in TNBC. Our research is geared towards improving population health as it aims to combat this aggressive form of breast cancer by developing a therapeutic strategy to be used in the clinic while improving our understanding of breast cancer resistance.
Competitiondate
201911
Approvedterm2
3 yrs 0 mth
Pinamesdelim
El-Sahli, Sara
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~